One of the most common questions asked by kidney transplant candidates and their families is:

“Can a kidney transplant be successful if the donor and recipient have no HLA match at all?”

The answer is yes.
Although HLA matching remains an important immunological factor, modern kidney transplantation relies on a much broader evaluation. Advances in immunosuppressive therapy, improved laboratory testing, and careful post-transplant monitoring have made successful transplantation possible even when there is a complete HLA mismatch between the donor and recipient.
Today, many transplant centers around the world routinely perform successful kidney transplants with minimal or even zero HLA matching.

What Is HLA?

Human Leukocyte Antigens (HLA) are proteins located on the surface of most cells in the body. These proteins help the immune system distinguish between the body’s own tissues and foreign tissues.
Since a transplanted kidney carries the donor’s HLA proteins, the recipient’s immune system may recognize them as foreign and attempt to attack the new organ.
Generally, the greater the HLA compatibility between donor and recipient, the lower the immunological risk. However, HLA matching is only one factor among many that determine transplant success.

Does Zero HLA Match Mean the Transplant Will Fail?

No.
Years ago, HLA compatibility played a much larger role in donor selection because immunosuppressive medications were less effective than they are today.
Modern immunosuppressive therapy has dramatically improved transplant outcomes. As a result, many patients with complete HLA mismatch experience excellent kidney function for many years after transplantation.
For this reason, most experienced transplant centers no longer consider zero HLA matching alone to be a contraindication for kidney transplantation.

Why Are Crossmatch and DSA More Important?

Although HLA matching provides useful information, two laboratory tests are often even more important before transplantation:
Negative Crossmatch
A Crossmatch test determines whether the recipient already has antibodies capable of immediately attacking the donor’s cells.
A negative Crossmatch indicates that these harmful antibodies are absent, making hyperacute rejection extremely unlikely.
This is one of the strongest indicators that transplantation can proceed safely.
Negative Donor-Specific Antibodies (DSA)
Donor-Specific Antibodies (DSA) are antibodies directed specifically against the donor’s HLA molecules.
A negative DSA test means the recipient has no pre-existing antibodies targeting the donor kidney.
Patients with both negative Crossmatch and negative DSA generally have a favorable immunological profile for transplantation, even when HLA matching is poor.

What Happens If There Is Zero HLA Match but Both Crossmatch and DSA Are Negative?

In this situation, kidney transplantation is generally considered safe from an immunological standpoint.
The transplanted kidney often begins functioning normally because the recipient’s immune system has not yet developed antibodies against the donor.
Many patients with this profile achieve excellent short-term and long-term transplant outcomes.

Can Problems Develop Years Later?

Possibly—but not necessarily.
Although patients with complete HLA mismatch often do very well, they have a somewhat higher lifetime risk of developing de novo Donor-Specific Antibodies (de novo DSA) after transplantation.
These antibodies are not present before surgery but may develop months or years later as the immune system gradually recognizes the donor kidney.
If de novo DSA develops, it can increase the risk of chronic antibody-mediated rejection (chronic AMR), which may slowly reduce kidney function over time.
However, this is not inevitable.
Many recipients with complete HLA mismatch never develop clinically significant antibodies and continue to enjoy excellent kidney function for decades.

What Factors Increase Long-Term Kidney Graft Survival?

Long-term kidney transplant success depends on much more than HLA compatibility.
Whether a patient has a perfect HLA match or a complete mismatch, the following factors have the greatest influence on long-term graft survival.

1. Strict Adherence to Immunosuppressive Medication

This is the single most important factor affecting transplant success.
Immunosuppressive medications prevent the immune system from attacking the transplanted kidney.
Missing doses, taking medications irregularly, or stopping treatment without medical supervision significantly increases the risk of both acute and chronic rejection.
For patients with complete HLA mismatch, strict medication adherence becomes even more important because their immune system may be more likely to recognize the donor kidney as foreign.

2. Regular Follow-Up and Laboratory Monitoring

Routine follow-up visits allow physicians to detect early signs of rejection before permanent kidney damage occurs.
Monitoring usually includes:
Serum creatinine
Estimated GFR (eGFR)
Urinalysis
Urine protein measurement
Blood levels of immunosuppressive medications
Blood pressure assessment
Blood glucose testing
Viral infection screening when indicated
Early intervention often prevents irreversible graft injury.

3. Blood Pressure Control

High blood pressure is one of the leading causes of long-term damage to transplanted kidneys.
Maintaining blood pressure within the recommended range protects the small blood vessels inside the kidney and slows the progression of chronic graft injury.

4. Diabetes Management

Poor blood sugar control damages blood vessels throughout the body, including those supplying the transplanted kidney.
Patients with diabetes should work closely with their healthcare team to maintain optimal glucose control in order to preserve kidney function.

5. Prevention and Early Treatment of Infections

Because transplant recipients require lifelong immunosuppressive therapy, they are more susceptible to bacterial, viral, and fungal infections.
Prompt diagnosis and treatment of infections not only protects overall health but may also reduce immune activation that could contribute to graft injury.

6. Monitoring for Donor-Specific Antibodies (DSA)

Not every transplant recipient requires routine DSA monitoring.
However, patients with higher immunological risk—including those with significant HLA mismatches, previous kidney transplants, unexplained deterioration in kidney function, or previous rejection episodes—may benefit from periodic DSA testing.
Detecting newly developed antibodies early allows transplant specialists to intervene before chronic antibody-mediated rejection causes irreversible damage.
Does This Advice Apply Only to Patients with Zero HLA Match?
No.
These recommendations apply to every kidney transplant recipient, regardless of the degree of HLA compatibility.
However, recipients with complete or significant HLA mismatch should be especially diligent about medication adherence and long-term follow-up because their lifetime risk of developing donor-specific antibodies is generally higher.
This does not mean they are destined to lose the transplant.
It simply means that careful long-term monitoring becomes even more important.

Can Patients with Zero HLA Match Live Normally After Transplantation?

Absolutely.
Many kidney transplant recipients with complete HLA mismatch maintain excellent kidney function for 10, 15, 20 years, or even longer.
The long-term success of a kidney transplant depends far more on proper medical management, consistent medication use, and regular follow-up than on HLA matching alone.
Even recipients with perfect HLA compatibility can lose a transplanted kidney if immunosuppressive medications are not taken correctly.

Conclusion

A complete HLA mismatch should not automatically discourage patients from pursuing kidney transplantation.
When the following conditions are present:
Negative Crossmatch
Negative Donor-Specific Antibodies (DSA)
A medically suitable donor
Careful evaluation by an experienced transplant team
Kidney transplantation can achieve excellent outcomes despite complete HLA mismatch.
While poor HLA compatibility may increase the long-term risk of developing donor-specific antibodies, modern immunosuppressive therapy and careful lifelong follow-up have made long-term graft survival possible for thousands of patients worldwide.
Successful kidney transplantation is determined not by HLA matching alone, but by the combination of proper donor selection, advanced immunological testing, expert medical care, and lifelong commitment to post-transplant treatment.